title: Effect of chlordimeform and clonidine on the turnover of P-octopamine in rat hypothalamus and striatum.
abstract: The effect of the invertebrate octopamine agonists chlordimeform and clonidine on the concentration and turnover of p-octopamine and m- and p-tyramine was determined in rat hypothalamus and striatum. Clonidine (0.25 mg/Kg, s.c.) did not alter the concentration of p-octopamine in the hypothalamus or p-tyramine in the striatum. Administration of chlordimeform (50 mg/Kg, i.p.) resulted in an increase in p- and m-tyramine concentrations in the striatum but not that of p-octopamine in the hypothalamus. This increase in the tyramine isomers is consistent with the ability of chlordimeform and its metabolite, demethylchlordimeform, to inhibit monoamine oxidase (MAO). The concurrent administration of chlordimeform (50 mg/Kg, i.p.) and pargyline (75 mg/Kg, i.p.) produced a significant decrease in the accumulation of octopamine in the hypothalamus but not in the striatum. In contrast, the concurrent administration of clonidine (0.25 mg/Kg, s.c.) and pargyline (75 mg/Kg, i.p.) caused a significant decrease in the accumulation of octopamine in the striatum but not hypothalamus. These results show that the turnover of octopamine in the hypothalamus and striatum is decreased by chlordimeform and clonidine, respectively. Further, clonidine is known to modulate the turnover of amines in mammalian noradrenergic nerve terminals by an action at presynaptic adrenergic receptors. These data suggest that two mechanisms, one involving presynaptic adrenergic receptors in the striatum, and the other involving as yet unidentified receptors in the hypothalamus, modulate the turnover of octopamine in the mammalian brain.
authors.forename: P H
authors.initials: PH
authors.lastname: Duffield
authors.forename: D F
authors.initials: DF
authors.lastname: Dougan
authors.forename: D N
authors.initials: DN
authors.lastname: Wade
authors.forename: A M
authors.initials: AM
authors.lastname: Duffield
mesh_terms: D000578:Amidines / Q000494:pharmacology*; D000818:Animals; D002742:Chlorphenamidine / Q000494:pharmacology*; D003000:Clonidine / Q000494:pharmacology*; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism*; D007031:Hypothalamus / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology; D009638:Norepinephrine / Q000378:metabolism; D009655:Octopamine / Q000378:metabolism*; D010293:Pargyline / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D014439:Tyramine / Q000378:metabolism
chemical_list: D000578:Amidines; D008996:Monoamine Oxidase Inhibitors; D009655:Octopamine; D010293:Pargyline; D002742:Chlorphenamidine; D003000:Clonidine; D009638:Norepinephrine; D014439:Tyramine